Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/INCYTE-CORPORATION-9675/news/Incyte-prasentiert-positive-52-Wochen-Daten-aus-Phase-2b-Studie-zur-Evaluierung-von-Povorcitinib-I-45043545/?utm_source=whatsapp&utm_medium=social&utm_campaign=share